
Ez-PAVE: LDL target below 55 mg/dL cut major events 33% versus below 70 mg/dL
Shared summary of the Ez-PAVE NEJM trial randomizing 3,048 patients with ASCVD to LDL target below 1.4 mmol/L (55 mg/dL) or below 1.8 mmol/L (70 mg/dL) for 3 years. The intensive target had fewer events with equivalent safety, supporting combination lipid-lowering earlier.


